PPARγ disease gene network and identification of therapeutic targets for prostate cancer

Journal of Drug Targeting

Volumn 19, Issue 9, 2011, Pages 781-796

  Venkatachalam, Gireedhar ^a   Kumar, Alan Prem ^a,d   Sakharkar, Kishore R ^e   Thangavel, Sindhu ^b   Clement, Marie Véronique ^a,c   Sakharkar, Meena Kishore ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e SCHOOL OF PHYSICS   (Malaysia)

Author keywords

Direct repeat 2; Genome wide DR1 and DR2 PPAR genes; PPAR disease gene network; PPAR proteinprotein network; PPAR target genes in prostate cancer

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOGLYCERATE KINASE; PHOSPHOGLYCERATE KINASE 1; PROTEIN KINASE C ZETA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR GENE;

CELL LINE, TUMOR; GENE REGULATORY NETWORKS; HUMANS; MALE; NEOPLASMS; NERVOUS SYSTEM DISEASES; PHOSPHOGLYCERATE KINASE; PPAR GAMMA; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTEIN KINASE C;

EID: 80054692069     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2011.568062     Document Type: Article

References (83)

1. Altenberg B, Greulich KO. (2004). Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics, 84, 1014-1020 (Pubitemid 39469126)
2. Aronowski J. (2002). Peroxisome proliferator-activated receptorreduces damage produced by focal ischemia. Abstr-Soc Neurosci, Program No. 389.6
3. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM. (1999). PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell, 4, 585-595 (Pubitemid 29531138)
4. Bernhagen J, Bacher M, Calandra T, Metz CN, Doty SB, Donnelly T, Bucala R. (1996). An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med, 183, 277-282 (Pubitemid 26028767)
5. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, David JR. (1999). Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med, 189, 341-346 (Pubitemid 29063255)
6. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC. (2002). Protective action of the peroxisome proliferatoractivated receptor-gamma agonist pioglitazone in a mouse model of Parkinsons disease. J Neurochem, 82, 615-624 (Pubitemid 34831499)
7. Butler R, Mitchell SH, Tindall DJ, Young CY. (2000). Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. Cell Growth Differ, 11, 49-61 (Pubitemid 30078666)
8. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hültner L, Heumann D, Mnnel D, Bucala R, Glauser MP. (2000). Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med, 6, 164-170 (Pubitemid 30082360)
9. Calandra T, Spiegel LA, Metz CN, Bucala R. (1998). Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proc Natl Acad Sci USA, 95, 11383-11388 (Pubitemid 28450137)
10. Chang TH, Szabo E. (2000). Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res, 60, 1129-1138 (Pubitemid 30129556)
11. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, Christmas R, Avila-Campilo I, Creech M, Gross B, Hanspers K, Isserlin R, Kelley R, Killcoyne S, Lotia S, Maere S, Morris J, Ono K, Pavlovic V, Pico AR, Vailaya A, Wang PL, Adler A, Conklin BR, Hood L, Kuiper M, Sander C, Schmulevich I, Schwikowski B, Warner GJ, Ideker T, Bader GD. (2007). Integration of biological networks and gene expression data using Cytoscape. Nat Protoc, 2, 2366-2382
12. Crooks GE, Hon G, Chandonia JM, Brenner SE. (2004). WebLogo: a sequence logo generator. Genome Res, 14, 1188-1190 (Pubitemid 38811555)
13. Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB. (2004). Protection by pioglitazone in the MPTP model of Parkinsons disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem, 88, 494-501 (Pubitemid 38084565)
14. del Vecchio MT, Tripodi SA, Arcuri F, Pergola L, Hako L, Vatti R, Cintorino M. (2000). Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment-related changes. Prostate, 45, 51-57
15. Della Peruta M, Giagulli C, Laudanna C, Scarpa A, Sorio C. (2010). RHOA and PRKCZ control different aspects of cell motility in pancreatic cancer metastatic clones. Mol Cancer, 9, 61
16. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. (2003). DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol, 4, P3
17. Du P, Feng G, Flatow J, Song J, Holko M, Kibbe WA, Lin SM. (2009). From disease ontology to disease-ontology lite: statistical methods to adapt a general-purpose ontology for the test of gene-ontology associations. Bioinformatics, 25, i63-i68
18. DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA. (1998). The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis, 19, 49-53 (Pubitemid 28376825)
19. Elstner E, Müller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP. (1998). Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA, 95, 8806-8811
20. Evans RM, Barish GD, Wang YX. (2004). PPARs and the complex journey to obesity. Nat Med, 10, 355-361. (Pubitemid 38508511)
21. Feilchenfeldt J, Bründler MA, Soravia C, Tötsch M, Meier CA. (2004) Peroxisome proliferator-activated receptors (PPARs) and associated transcription factors in colon cancer: reduced expression of PPARgamma-coactivator 1 (PGC-1). Cancer Lett, 203, 25-33
22. Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Heneka MT. (2002). Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol, 51, 694-702 (Pubitemid 34568847)
23. Fontaine C, Dubois G, Duguay Y, Helledie T, Vu-Dac N, Gervois P, Soncin F, Mandrup S, Fruchart JC, Fruchart-Najib J, Staels B. (2003). The orphan nuclear receptor Rev-Erbalpha is a peroxisome proliferator-activated receptor (PPAR) gamma target gene and promotes PPARgamma-induced adipocyte differentiation. J Biol Chem, 278, 37672-37680 (Pubitemid 37175291)
24. Fukushima M, Sasaki H, Fukushima S. (1994). Prostaglandin J2 and related compounds. Mode of action in G1 arrest and preclinical results. Ann N Y Acad Sci, 744, 161-165 (Pubitemid 26005820)
25. Gaci O. A topological description of hubs in amino acid interaction networks (2010). Adv Bioinform., 257512. (No other details in PubMed)
26. Gervois P, Chopin-Delannoy S, Fadel A, Dubois G, Kosykh V, Fruchart JC, Najib J, Laudet V, Staels B. (1999). Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element. Mol Endocrinol, 13, 400-409 (Pubitemid 29113872)
27. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. (1999). Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia, 1, 330-339
28. Gupta RA, Brockman JA, Sarraf P, Willson TM, DuBois RN. (2001). Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J Biol Chem, 276, 29681-29687
29. Han S, Inoue H, Flowers LC, Sidell N. (2003). Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells. Clin Cancer Res, 9, 4627-4635 (Pubitemid 37248424)
30. Han SW, Greene ME, Pitts J, Wada RK, Sidell N. (2001). Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma cells. Clin Cancer Res, 7, 98-104 (Pubitemid 32110211)
31. Hara M, Alcoser SY, Qaadir A, Beiswenger KK, Cox NJ, Ehrmann DA. (2002). Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. J Clin Endocrinol Metab, 87, 772-775 (Pubitemid 34158251)
32. Heneka MT, Landreth GE, Feinstein DL. (2001). Role for peroxisome proliferator-activated receptor-gamma in Alzheimers disease. Ann Neurol, 49, 276 (Pubitemid 32158009)
33. Houseknecht KL, Cole BM, Steele PJ. (2002). Peroxisome proliferatoractivated receptor gamma (PPARgamma) and its ligands: a review. Domest Anim Endocrinol, 22, 1-23 (Pubitemid 34438654)
34. Hsueh WA, Bruemmer D. (2004). Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension, 43, 297-305 (Pubitemid 38174129)
35. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. (2003). Cancer statistics. CA Cancer J Clin., 53,1, 5-26
36. Kamimura A, Kamachi M, Nishihira J, Ogura S, Isobe H, Dosaka- Akita H, Ogata A, Shindoh M, Ohbuchi T, Kawakami Y. (2000). Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer, 89, 334-341 (Pubitemid 30489881)
37. Keshamouni VG, Arenberg DA, Reddy RC, Newstead MJ, Anthwal S, Standiford TJ. (2005). PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia, 7, 294-301 (Pubitemid 40411641)
38. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R, Shafreen B, Venugopal A, Balakrishnan L, Marimuthu A, Banerjee S, Somanathan DS, Sebastian A, Rani S, Ray S, Harrys Kishore CJ, Kanth S, Ahmed M, Kashyap MK, Mohmood R, Ramachandra YL, Krishna V, Rahiman BA, Mohan S, Ranganathan P, Ramabadran S, Chaerkady R, Pandey A. (2009). Human Protein Reference Database-2009 update. Nucleic Acids Res, 37, D767-D772
39. Kim IK, Lee JH, Sohn HW, Kim HS, Kim SH. (1993). Prostaglandin A2 and delta 12-prostaglandin J2 induce apoptosis in L1210 cells. FEBS Lett, 321, 209-214
40. Krentz AJ, Friedmann PS. (2006). Type 2 diabetes, psoriasis and thiazolidinediones. Int J Clin Pract, 60, 362-363 (Pubitemid 43337620)
41. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP. (1998). Ligand for peroxisome proliferatoractivated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res, 58, 3344-3352 (Pubitemid 28371075)
42. Kumar AP, Quake AL, Chang MKX, Lim KSY, Eng CB, Singh R, Hewitt RE, Salto-Tellez M, Pervaiz S, Clement MV. (2009). Repression of the Na+/H+ exchanger 1 expression by PPARg activation is a potential new approach for specific inhibition of tumor cells growth in vitro and in vivo. Cancer Res., 69, 22, 8636-8644
43. Kumar AP, Piedrafita FJ, Reynolds WF. (2004). Peroxisome proliferatoractivated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the ?463GA promoter polymorphism. J Biol Chem, 279, 8300-8315 (Pubitemid 38294722)
44. Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, Weedon H, Holdsworth SR, Bucala R, Morand EF. (1999). Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum, 42, 1601-1608 (Pubitemid 30263626)
45. Leech M, Metz C, Santos L, Peng T, Holdsworth SR, Bucala R, Morand EF. (1998). Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum, 41, 910-917 (Pubitemid 28225792)
46. Lehrke M, Lazar MA. (2005). The many faces of PPARgamma. Cell, 123, 993-999
47. Lieberthal W, Menza SA, Levine JS. (1998). Graded ATP depletion can cause necrosis or apoptosis of cultured mouse proximal tubular cells. Am J Physiol, 274, F315-F327
48. Makita H, Nishimura M, Miyamoto K, Nakano T, Tanino Y, Hirokawa J, Nishihira J, Kawakami Y. (1998). Effect of anti-macrophage migration inhibitory factor antibody on lipopolysaccharideinduced pulmonary neutrophil accumulation. Am J Respir Crit Care Med, 158, 573-579 (Pubitemid 28378189)
49. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. (1995). The nuclear receptor superfamily: the second decade. Cell, 83, 835-839
50. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR, Lampidis TJ. (2004). 2-Deoxy-dglucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res, 64, 31-34 (Pubitemid 38114078)
51. Mikulowska A, Metz CN, Bucala R, Holmdahl R. (1997). Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol, 158, 5514-5517 (Pubitemid 127681261)
52. Mössner R, Schulz U, Krüger U, Middel P, Schinner S, Füzesi L, Neumann C, Reich K. (2002). Agonists of peroxisome proliferatoractivated receptor gamma inhibit cell growth in malignant melanoma. J Invest Dermatol, 119, 576-582
53. Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. (2000). Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res, 60, 5558-5564
54. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM. (1998). Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell, 1, 465-470 (Pubitemid 128378895)
55. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM. (1998). Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell, 1, 465-470 (Pubitemid 128378895)
56. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW. (2000). Effects of ligand activation of peroxisome proliferatoractivated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA, 97, 10990-10995
57. Nakashiro K, Begum NM, Uchida D, Kawamata H, Shintani S, Sato M, Hamakawa H. (2003). Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor gamma. Oral Oncol, 39, 855-861 (Pubitemid 38373469)
58. Nielsen R, Pedersen TA, Hagenbeek D, Moulos P, Siersbaek R, Megens E, Denissov S, Brgesen M, Francoijs KJ, Mandrup S, Stunnenberg HG. (2008). Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes Dev, 22, 2953-2967
59. Niino M, Iwabuchi K, Kikuchi S, Ato M, Morohashi T, Ogata A, Tashiro K, Onoé K. (2001). Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. J Neuroimmunol, 116, 40-48 (Pubitemid 32322638)
60. Nijsten T, Geluyckens E, Colpaert C, Lambert J. (2005). Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors. J Cutan Pathol, 32, 340-347 (Pubitemid 40547792)
61. Ondrey F. (2009). Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res, 15, 2-8
62. Osborne JD, Flatow J, Holko M, Lin SM, Kibbe WA, Zhu LJ, Danila MI, Feng G, Chisholm RL. (2009). Annotating the human genome with disease ontology. BMC Genom, 10 (Suppl 1), S6
63. Panigrahy D, Huang S, Kieran MW, Kaipainen A. (2005). PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther, 4, 687-693 (Pubitemid 41351164)
64. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH. (2001). Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol, 11, 764-768 (Pubitemid 32442793)
65. Rhead B, Karolchik D, Kuhn RM, Hinrichs AS, Zweig AS, Fujita PA, Diekhans M, Smith KE, Rosenbloom KR, Raney BJ, Pohl A, Pheasant M, Meyer LR, Learned K, Hsu F, Hillman-Jackson J, Harte RA, Giardine B, Dreszer TR, Clawson H, Barber GP, Haussler D, Kent WJ. (2010). The UCSC Genome Browser database: update 2010. Nucleic Acids Res, 38, D613-D619
66. Rossi AG, Haslett C, Hirani N, Greening AP, Rahman I, Metz CN, Bucala R, Donnelly SC. (1998). Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma. J Clin Invest, 101, 2869-2874 (Pubitemid 28294596)
67. Sakharkar MK, Sakharkar KR. (2008). Genetic and pharmacological interaction network of targets and drugs. Int J Integ Biol, 4, 1-8
68. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM. (1998). Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med, 4, 1046-1052 (Pubitemid 28417337)
69. Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, Okuyama T, Rumi MA, Fukuda R, Nagasue N, Kinoshita Y. (2000). Expression of peroxisome proliferator-activated receptor (PPAR) gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer, 83, 1394-1400
70. Scardoni G, Petterlini M, Laudanna C. (2009). Analyzing biological network parameters with CentiScaPe. Bioinformatics, 25, 2857-2859.
71. Scatena R, Bottoni P, Pontoglio A, Mastrototaro L, Giardina B. (2008). Glycolytic enzyme inhibitors in cancer treatment. Expert Opin Investig Drugs, 17, 1533-1545
72. Shimazu T, Inoue I, Araki N, Asano Y, Sawada M, Furuya D, Nagoya H, Greenberg JH. (2005). A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke, 36, 353-359 (Pubitemid 40170822)
73. Singh RP, Agarwal R. (2006). Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer, 13, 751-778 (Pubitemid 44763256)
74. Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, Schultz PG, Powell SM, Moskaluk CA, Frierson HF Jr, Hampton GM. (2001). Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res, 61, 7388-7393 (Pubitemid 32995021)
75. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE. (2005). Peroxisome proliferator-activated receptorgamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience, 130, 685-696 (Pubitemid 39601441)
76. Theocharis S, Kanelli H, Politi E, Margeli A, Karkandaris C, Philippides T, Koutselinis A. (2002). Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer,36,3, 249-255 (Pubitemid 34497122)
77. Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R, Diemer K, Muruganujan A, Narechania A. (2003). PANTHER: a library of protein families and subfamilies indexed by function. Genome Res, 13, 2129-2141 (Pubitemid 37161770)
78. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM, Spiegelman BM. (1997). Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA, 94, 237-241 (Pubitemid 27027193)
79. Venkatachalam G, Kumar AP, Yue LS, Pervaiz S, Clement MV, Sakharkar MK. (2009). Computational identification and experimental validation of PPRE motifs in NHE1 and MnSOD genes of human. BMC Genomics, 10 (Suppl 3), S5
80. Venkatachalam G, Sakharkar MK, Kumar AP, Clement MV. (2009). PPRESearch: Peroxisome Proliferator Activator Element Search Database. Int J Integ Biol, 8, 37-42
81. Wang J, Wang J, Dai J, Jung Y, Wei CL, Wang Y, Havens AM, Hogg PJ, Keller ET, Pienta KJ, Nor JE, Wang CY, Taichman RS. (2007). A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer Res, 67, 149-159 (Pubitemid 46142770)
82. Warburg O, Posener K, Negelein E. (1924). Ueber den Stoffwechsel der Tumoren. Biochemische Zeitschrift, 152, 319-344
83. Watson GS, Craft S. (2003). The role of insulin resistance in the pathogenesis of Alzheimers disease: implications for treatment. CNS Drugs, 17, 27-45 (Pubitemid 36044347)